$NVAX rising wedge forming on the dailyThere is a rising wedge forming on $NVAX daily chart. Bio stocks could break out to the topside with any news but this is a very bearish reversal pattern. Look for a play when it breaks the trend either way. Gap to the lower end could be filled. Shortby poetic1444
NVAX'S VACCINE FOR FLU IS PROMISING! Hello traders! Good news from Novavax! The chances of approval for flu vaccine candidate NanoFlu seems actually quite good! Moreover, if we look at the chart, we can see that the price is on a strong uptrend that doesn't seem to want to stop. The bullish momentum is still strong! Remember to put a stop loss in order to secure your capital! Not a financial advice. Enjoy your trade! Longby vf_investment8
NOVAVAX announcementHey guys, NOVAVAX is in a compression zone, sinal to purchase high volume of sales in recent days. It may break the balance area from above at the same time, great hope of breaking out the second area while passing. Please LIKE & FOLLOW, thank you! Shortby stephanelibatd115
Novavax Announces $1.6 Billion Funding from Operation Warp SpeedNovavax Announces $1.6 Billion Funding from Operation Warp Speed has been selected to participate in Operation Warp Speed (OWS), a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 in 2021. Novavax has been awarded $1.6 billion by the federal government to complete late-stage clinical development, including a pivotal Phase 3 clinical trial; establish large-scale manufacturing; and deliver 100 million doses of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate, as early as late 2020. NVX‑CoV2373 consists of a stable, prefusion protein made using its proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. by AlenCiken113
Nvax to Receive up to $388 Million Funding from CEPI CASE STUDY1. Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing -Funds clinical development of NVX-CoV2373 through Phase 2 -Supports rapid scale-up of vaccine manufacturing -Allows for increased production of Matrix-M adjuvant -Reserves global large-scale manufacturing capacity A Phase 1/2 clinical trial with the Phase I portion starting this month in Australia and the Phase 2 portion conducted in multiple countries following successful Phase 1 top-line results that are expected in July. ir.novavax.com 2. Novavax Reports First Quarter 2020 Financial Results -CEPI increases investment up to $388 million for NVX‑CoV2373 vaccine development & manufacturing -NVX‑CoV2373 Phase I trial initiating in May with preliminary results in July -NanoFlu recently achieved all primary endpoints in pivotal Phase 3 clinical trial ir.novavax.comby AlenCiken4
NVAX: Key Points to Look AtEarlier today, I put a target of at most $115 and later was convinced to do a sell off at $108. Many people thought this would go straight to $150+, but it looks like the positive wedge have peaked. Right now, I currently think the dip will likely be at the $90 price point, but an important factor to consider is closely monitoring movement at the $95 mark. The advanced decline ratio seems to be peaking, and the FIB retracement also showed that it was towards its high point in the morning for the current correlation trend. As always, invest in your own risk and proceed with caution. This is on an opinion based basis.Shortby gamer456148113
Long NVAX (Possibly day trade)As illustrated. Sell half at 1R (106.85), 1/4 at 2R. If it runs well, keep the remaining 1/4 for free run. If not, sell all.Longby JJWinWinUpdated 3
+$900 today trading $BA with 2/3 winsHi Guys, changed up the strategy a little today and $BA was not easy to trade. Enjoy, Enda05:46by TrendSpotter15
[NVAX] Novavax: Update - 1.6 billion funded!I still believe NVAX has a lot of potential and I'll say it again. My idea is clear that its NanoParticle and Matrix-M Adjuvant tech makes it a prime candidate for a COVID-19 vaccines. Even if it doesn't make it first (or ever), it still has major potential for the seasonal influenza (w/ NanoFlu) and its Respiratory Syncytial Virus (RSV) vaccine. Check out my original post that is linked. Today's News: 1. www.cnbc.com 2. www.fool.comLongby traderman0017
NOVAVAX - long term targetsThese are my thoughts on Novavax. They are meant to give you an idea, not trading advice. As written in the textbooks, gaps in a downtrend always get filled in an uptrend. We already filled gap 1. I believe it's time to start filling gap 2, witch is gigantic. Novavax is receiving a lot of financial support for making a Covid19 vaccin, so expectations are high for now. It's one of the stronger stocks in the market at this moment, working together with Biotechnology. As you can see on the charts, we have formed a similar pattern as we did in April 2020. I don't know how fast gap 2 can get filled, but as soon as we started filing gap 1, things skyrocketed. I'm very excited to see how this will play out, and I hope it can help you. Please note that Novavax is a very volatile stock, things can change very fast over night. Be careful when entering your position in this stock! Longby AXLPUpdated 151514
NVAX a bit ahead of itself?This one looks just to have gone a bit too far, too fast. Very extended here; looking for a pullback to 70-72.5 in the next day or two. hourly MACD rolling; RSI in nutso land; way outside of the 1 stdev bollingers daily; tracked in on hourly.Shortby tacosaurusUpdated 6
NVAX Short. NVAX looking over bought here on the charts. Expecting people to take some profits and a small fall from grace. Target is ~69. However could go lower with enough sellers. Stop 87.5. Best of luck, --d0xShortby Parad0x_Updated 225
NVAX Long - $150 Target?I've been following NVAX since price was at $12. Fundamentally they have one of the most promising COVID vaccines and their Nano Flu shot beat Sanify's flu shot, whos been a market majority holder in that aspect. Technically, we've tapped that $150+ zone 8 out of the last 9 fast rises over since the company IPO'd in 1996. Each of the rises have been driven by pandemic viruses..ie, swine flu, bird flu, H1N1, etc. We have 4 days until the quarterly candle closes. If we close strong, we'd of closed above the coral, and momentum and RSI are correlating. I think we will see a short term sell off at the psychological $100 level. How much? I could see $80-$85 be a good rebuy zone to push price up to t $125 then $150. Buyers at $80, will probably be looking for a double on their investment which would put price at $160. Let me know what you think!Longby allout067710
Novavax (NVAX) stock price is on track...for now [LONG]Just re-iterating my previous assertion (guess) that NVAX is on course for massive gains in the long-term. Doesn't mean it's a great company but this pandemic has initiated a similar pattern in the past. They have several great developments in the works: NanoFlu, RSV F, and a COVID-19 vaccine candidate. See my previous posts especially the related one. This is purely speculation based on their pipeline. This is not financial advice.Longby traderman001Updated 337
Well, I mean.THIS IS NOT ANY FINANCIAL ADVICE, just some info. Quite simply this is a short IMO, RSI is at 90! And there is bearish divergence.Shortby VentureBroker3
NVAX: Bullish pennantBullish Pennant, confirmed PPS above 50MA and 200MA High ATR, and climbing Ascending 200MA, bullish 250RSI above 50, bullish R/R almost 10, high If confirmed: Goal #1 = 80.27$$ Goal #2 = 106.02$ Longby LeLaf11116
Novavax, Inc. (NVAX) long.All description on the chart. Please, don't forget to like and follow. Thank you.Longby chorny.capitalUpdated 6
$NVAX Sits at Key CrossroadsNVAX shares just broke back above the critical $50 level. Its current pattern is either a constructive pause in a continuing trend, or a failure in the making organized as a violated bearish descending triangle with a bear trigger at $45. The straddle is in play.by GregFolin6
Nvax in depth analysis and view on a stockFundamentals : Previous Close- 44.43 Open- 45.55 Bid- 45.00 x 1300 Ask- 45.40 x 1000 Day's Range- 43.60 - 45.76 52 Week Range- 3.54 - 61.50 Volume- 3,231,807 Avg. Volume- 9,264,854 Market Cap- 2.673B Beta (5Y Monthly)- 1.41 PE Ratio (TTM)- N/A EPS (TTM)- -3.83 Earnings Date- May 10, 2020 Forward Dividend & Yield- N/A (N/A) Ex-Dividend Date- N/A 1y Target Est- 51.80 Stock can surge up in the future because of the news. That does not mean that is a great investment. Nvax is mostly traded intraday, and is not good for longer term. My analysis is only for entertainment only and i do not recommend taking any of my trades because of the risk. I offer stock trading mentorship for free, later i will probably offer paid mentorship. I am a trader at an investment firm. If you have any king of questions feel free to ask. If you need help feel free to ask. If you want to learn more feel free to contact me. If you want to get a funded account up to 280.000$, mentorship and professional knowledge contact me. From May this programs are not available for US residents. BlackStock by UnknownUnicorn702546010
NOVAVAX in an Ascending breakout. Potential upside of 30%NOVAVAX close to a breakout point. Risk reward 2:1. Longby InvestirecomeiMigliori5